JP2024540044A5 - - Google Patents

Info

Publication number
JP2024540044A5
JP2024540044A5 JP2024525160A JP2024525160A JP2024540044A5 JP 2024540044 A5 JP2024540044 A5 JP 2024540044A5 JP 2024525160 A JP2024525160 A JP 2024525160A JP 2024525160 A JP2024525160 A JP 2024525160A JP 2024540044 A5 JP2024540044 A5 JP 2024540044A5
Authority
JP
Japan
Prior art keywords
drug
cycle
mosnetuzumab
day
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024525160A
Other languages
English (en)
Japanese (ja)
Other versions
JP7846761B2 (ja
JP2024540044A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057439 external-priority patent/WO2023075798A1/en
Publication of JP2024540044A publication Critical patent/JP2024540044A/ja
Publication of JP2024540044A5 publication Critical patent/JP2024540044A5/ja
Priority to JP2025155232A priority Critical patent/JP2026004356A/ja
Application granted granted Critical
Publication of JP7846761B2 publication Critical patent/JP7846761B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024525160A 2021-10-29 2021-10-29 モスネツズマブおよびレナリドミドを用いた再発性/難治性濾胞性リンパ腫の処置方法 Active JP7846761B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025155232A JP2026004356A (ja) 2021-10-29 2025-09-18 モスネツズマブおよびレナリドミドを用いた再発性/難治性濾胞性リンパ腫の処置方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/057439 WO2023075798A1 (en) 2021-10-29 2021-10-29 Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025155232A Division JP2026004356A (ja) 2021-10-29 2025-09-18 モスネツズマブおよびレナリドミドを用いた再発性/難治性濾胞性リンパ腫の処置方法

Publications (3)

Publication Number Publication Date
JP2024540044A JP2024540044A (ja) 2024-10-31
JP2024540044A5 true JP2024540044A5 (cg-RX-API-DMAC7.html) 2025-05-20
JP7846761B2 JP7846761B2 (ja) 2026-04-15

Family

ID=86158448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024525160A Active JP7846761B2 (ja) 2021-10-29 2021-10-29 モスネツズマブおよびレナリドミドを用いた再発性/難治性濾胞性リンパ腫の処置方法
JP2025155232A Pending JP2026004356A (ja) 2021-10-29 2025-09-18 モスネツズマブおよびレナリドミドを用いた再発性/難治性濾胞性リンパ腫の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025155232A Pending JP2026004356A (ja) 2021-10-29 2025-09-18 モスネツズマブおよびレナリドミドを用いた再発性/難治性濾胞性リンパ腫の処置方法

Country Status (7)

Country Link
JP (2) JP7846761B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240093915A (cg-RX-API-DMAC7.html)
AU (1) AU2021471006A1 (cg-RX-API-DMAC7.html)
CA (1) CA3236111A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005105A (cg-RX-API-DMAC7.html)
PE (1) PE20241211A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023075798A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026006456A1 (en) * 2024-06-25 2026-01-02 Genentech, Inc. Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide
TW202615094A (zh) * 2024-08-28 2026-04-16 美商建南德克公司 使用莫蘇妥珠單抗與帕羅托珠單抗維多汀組合之皮下給藥治療癌症之方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021022815A2 (pt) 2019-05-14 2021-12-28 Genentech Inc Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina

Similar Documents

Publication Publication Date Title
EP3076972B1 (en) Cancer treatment with combination of plinabulin and taxane
JP2024530310A (ja) T細胞リンパ腫治療薬の調製におけるezh2阻害剤の使用
US8618083B2 (en) Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
WO2012072505A1 (en) Volasertib alone or in combination with cytarabine for treating acute myeloid leukemia
JP2024530189A5 (cg-RX-API-DMAC7.html)
JP2020516646A5 (cg-RX-API-DMAC7.html)
EP4322942A1 (en) Combination comprising everolimus and amcenestrant
JP2025509510A5 (cg-RX-API-DMAC7.html)
JP2019508476A5 (cg-RX-API-DMAC7.html)
CN110013478A (zh) 用于抗肿瘤试剂施用的方法
JP2022544485A5 (cg-RX-API-DMAC7.html)
JP2024517085A5 (cg-RX-API-DMAC7.html)
JP2024539476A5 (cg-RX-API-DMAC7.html)
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP2023011549A5 (cg-RX-API-DMAC7.html)
Paszkiewicz-Kozik et al. Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group
JP2022058873A5 (cg-RX-API-DMAC7.html)
RU2485956C2 (ru) Новая композиция для лечения побочных эффектов противораковой терапии
JP2025511403A5 (cg-RX-API-DMAC7.html)
JP2025521501A5 (cg-RX-API-DMAC7.html)
WO2025044079A1 (zh) 一种act001组合物的抗肿瘤用途
JP2022547061A5 (cg-RX-API-DMAC7.html)
JP2025509613A5 (cg-RX-API-DMAC7.html)
JP2024541257A5 (cg-RX-API-DMAC7.html)
EP2691104A1 (en) Ezatiostat for treating multiple myeloma